SymBio Pharmaceuticals Limited
4582シンバイオ製薬株式会社
Latest half-year results
First half · fiscal year to 2026-12 · filed 2026-08-10For the first half of the fiscal year to 2026-12: Revenue ¥0.5 billion (-27.3% YoY), Ordinary income ¥-3.6 billion, Net income ¥-3.6 billion.
| This period | Year on year | |
|---|---|---|
| Revenue | ¥470m | -27.3% |
| Ordinary profit | −¥3.6bn | — |
| Net profit to owners | −¥3.6bn | — |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4582/earnings-releases.
Financials
Japan GAAP · consolidated · fiscal year to 2025-12-31- Revenue
- ¥1.3bn
- Net income
- −¥4.8bn
- ROE
- —
- Equity ratio
- 23.9%
- Dividend / share
- —
- Employees
- 91
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | ¥1.3bn | −¥4.8bn | ¥3.9bn | ¥1.3bn | — | ¥-95.12 | −¥4.6bn |
| 2024-12-31 | ¥2.5bn | −¥3.8bn | ¥5.0bn | ¥4.2bn | — | ¥-85 | −¥3.4bn |
| 2023-12-31 | ¥5.6bn | −¥2.0bn | ¥8.2bn | ¥7.2bn | — | ¥-49.19 | −¥0.2bn |
| 2022-12-31 | ¥10.0bn | ¥1.2bn | ¥10.4bn | ¥8.5bn | 14.6% | ¥30.2 | ¥1.6bn |
Indicators
Computed by us from filings · fiscal year to 2025-12-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | — | — |
| Ordinary margin | -3.5544 | 0.6 |
| Equity ratio, % | 23.9 | 9.2 |
| Revenue growth | -0.4669 | 0.7 |
| Net income growth | -0.2459 | 20.8 |
| Operating cash flow / assets | -1.1831 | 0.1 |
Results wording balance: -1.00. Proprietary text method; it describes the wording only and does not interpret context.
Interest example: if all ¥2.0bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥10m. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.
Via /v1/companies/4582/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4582/votingOwnership changes
All companies →- 2026-11-04
Evo Fund reduced holdings in SymBio Pharmaceuticals Limited (4582) to 53.39% from 54.38%.
- 2026-10-22
Evo Fund reduced holdings in SymBio Pharmaceuticals Limited (4582) to 54.38% from 55.34%.
- 2026-10-02
Evo Fund reduced holdings in SymBio Pharmaceuticals Limited (4582) to 55.34% from 56.25%.
- 2026-09-18
Evo Fund reduced holdings in SymBio Pharmaceuticals Limited (4582) to 56.25% from 57.40%.
- 2026-09-09
Evo Fund raised holdings in SymBio Pharmaceuticals Limited (4582) to 57.40% from 6.44%.
- 2026-09-09
Holdings of Evo Fund in SymBio Pharmaceuticals Limited (4582) moved above 10% (6.44% -> 57.40%).
- 2026-09-09
Holdings of Evo Fund in SymBio Pharmaceuticals Limited (4582) moved above 20% (6.44% -> 57.40%).
- 2026-09-09
Holdings of Evo Fund in SymBio Pharmaceuticals Limited (4582) moved above 33.4% (6.44% -> 57.40%).
- 2026-09-09
Holdings of Evo Fund in SymBio Pharmaceuticals Limited (4582) moved above 50% (6.44% -> 57.40%).
- 2026-09-07
Evo Fund reduced holdings in SymBio Pharmaceuticals Limited (4582) to 6.44% from 26.61%.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| Evo Fund | 2025-07-22 – 2026-10-27 | +88,917,800 | +45.52pt | ¥86.31 | ¥47–153 |
| Evolution Capital Management LLC | 2025-07-22 – 2026-10-27 | +88,917,800 | +45.52pt | ¥86.31 | ¥47–153 |
| individual filer | 2026-07-29 – 2026-07-29 | +2,854,000 | +3.56pt | ¥84 | ¥84–84 |
| individual filer | 2025-01-10 – 2026-02-27 | +4,831,342 | +10.23pt | ¥170 | ¥158–194 |
| Heights Capital Management, Inc. | 2022-06-01 – 2024-07-18 | +2,000,000 | +5.13pt | ¥662 | ¥662–662 |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4582/trades.
5% filings
Large shareholding reports on 4582| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-11-04 | Evo Fund | 53.39% | −0.99pt | pure investment |
| 2026-10-22 | Evo Fund | 54.38% | −0.96pt | pure investment |
| 2026-10-02 | Evo Fund | 55.34% | −0.91pt | pure investment |
| 2026-09-18 | Evo Fund | 56.25% | −1.15pt | pure investment |
| 2026-09-09 | Evo Fund | 57.40% | +50.96pt | pure investment |
| 2026-09-07 | Evo Fund | 6.44% | −20.17pt | pure investment |
| 2026-08-25 | individual filer | 6.35% | 0.00pt | — |
| 2026-08-25 | individual filer | 6.35% | — | — |
| 2026-08-25 | Evo Fund | 26.61% | +2.79pt | pure investment |
| 2026-08-05 | Evo Fund | 23.82% | −3.73pt | pure investment |
Major shareholders
As of fiscal year end 2025-12-31| Shareholder | Shares | Ratio |
|---|---|---|
| individual holder | 1,684,200 | 2.83% |
| 楽天証券株式会社共有口 | 1,414,000 | 2.38% |
| 株式会社SBI証券 | 1,384,480 | 2.33% |
| MORGAN STANLEY ＆ CO. LLC | 951,028 | 1.60% |
| JPモルガン証券株式会社 | 542,472 | 0.91% |
| STATE STREET BANK AND TRUST COMPANY 510643 | 512,000 | 0.86% |
| individual holder | 466,800 | 0.78% |
| individual holder | 402,200 | 0.68% |
| individual holder | 336,000 | 0.56% |
| 日本証券金融株式会社 | 313,900 | 0.53% |
Get this as JSON
GET /v1/companies/4582
GET /v1/companies/4582/financials
GET /v1/companies/4582/details
GET /v1/companies/4582/segments
GET /v1/companies/4582/voting
GET /v1/companies/4582/tender-offers
GET /v1/companies/4582/indicators
GET /v1/companies/4582/earnings-releases
GET /v1/events?ticker=4582
GET /v1/companies/4582/trades
GET /v1/companies/4582/cross-holdings
GET /v1/companies/4582/brief